Alpha Cognition Is 'Under-Followed' As Alzheimer Drug Targets $2 Billion Long Term Care Market: Analyst
HC Wainwright initiated coverage on Alpha Cognition, noting a new twist on a tried-and-tested treatment paradigm.
HC Wainwright Reiterates Buy Rating for Capricor Therapeutics (NASDAQ:CAPR)
Capricor Therapeutics (NASDAQ:CAPR – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research ...
Immunovant’s batoclimab shows ‘impressive’ efficacy in MG, says H.C. Wainwright
Immunovant (IMVT) reported best absolute improvements with IMVT-1402 in myasthenia gravis and chronic inflammatory demyelinating ...
Allogene Therapeutics price target lowered to $8 from $9 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Allogene Therapeutics (ALLO) to $8 from $9 and keeps a Buy rating on the shares following ...
HC Wainwright Reiterates “Buy” Rating for Bit Digital (NASDAQ:BTBT)
Bit Digital (NASDAQ:BTBT – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $7.00 price ...
Fintel on MSN2d
HC Wainwright & Co. Downgrades Sutro Biopharma (STRO)
Fintel reports that on March 17, 2025, HC Wainwright & Co. downgraded their outlook for Sutro Biopharma (NasdaqGM:STRO) from ...
Fintel on MSN2d
HC Wainwright & Co. Initiates Coverage of Actuate Therapeutics (ACTU) with Buy Recommendation
Fintel reports that on March 17, 2025, HC Wainwright & Co. initiated coverage of Actuate Therapeutics (NasdaqGM:ACTU) with a ...
Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs ...
Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst
H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.
H.C. Wainwright Sticks to Their Hold Rating for Biotricity (BTCY)
In a report released today, Kevin Dede from H.C. Wainwright maintained a Hold rating on Biotricity (BTCY – Research Report). The company’s shares closed last Friday at $0.50.
Cantargia to Participate at H.C. Wainwright’s Annual Autoimmune & Inflammatory Virtual Conference
Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm: CANTA) today announced that Damian Marron, Interim CEO, will participate ...
Nasdaq16d
HC Wainwright & Co. Initiates Coverage of Perspective Therapeutics (CATX) with Buy Recommendation
Fintel reports that on March 13, 2025, HC Wainwright & Co. initiated coverage of Perspective Therapeutics (NYSEAM:CATX) with a Buy recommendation. As of March 4, 2025, the average one-year price ...